Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

Abstract

MRD levels independently predict OS and PFS in CLL. Therefore, MRD quantification might serve as a surrogate marker to assess treatment efficacy in randomized trials before clinical end points can be evaluated.

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia

“…17 Achievement of complete response to therapy with no minimal residual disease has been identified as an independent favorable prognostic factor. 18 Until further clinical investigation is complete, it is unknown whether ocaratuzumab will have the same or better efficacy compared with obinutuzumab when used for treatment of CLL.…”

A single tube 10‐color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia

“…Recent publications of initial therapy of previously untreated patients with CLL have shown that levels of post-treatment residual disease of below 0.01%, 0.01-1%, and over 1% have prognostic significance in terms of both PFS and OS (1,16). Direct comparison of samples at all levels of residual disease showed excellent correlation between the single tube 10-color assay and the 4 tube 4-color ISA assay.…”

“…Six patients were analyzed at various time points after reduced intensity allogeneic stem cell transplantation. As outlined in previous studies of CLL, residual disease levels of <0.01%, 0.01-1%, and >1% were taken to indicated levels of residual disease with significantly different prognostic outcomes (1). Normal blood and BM were obtained from bone marrow transplant donors.…”

“…The eradication of minimal residual disease (MRD) following treatment for chronic lymphocytic leukemia (CLL) predicts for improved outcome irrespective of the therapy used to achieve this goal (1)(2)(3). Patients achieving MRD negativity determined by highly sensitive flow cytometry or polymerase chain reaction demonstrate prolonged progression-free survival (PFS) and overall survival (OS).…”

Achieving Minimal Residual Disease Negative Status in CLL - a Good Point to Start Thinking about Life without Treatment: How to Check MRD Status?

“…The observed eradication of leukemia cells using commercially available methods can be crucial for the decision to complete the therapy. It has been proved that the assessment of MRD is helpful in estimating overall survival (OS), treatment-free survival (TFS) and progression-free survival (PFS), in the context of the treatment [5,19].…”